CALI BIOTPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1516 USD | 0.00% |
|
-21.82% | -89.96% |
| Jul. 05 | Calidi Biotherapeutics to Implement 1-For-10 Reverse Stock Split | MT |
| Jul. 02 | Calidi Biotherapeutics, Inc. announced that it has received $0.6 million in funding | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 100.5 | 53.55 | 9.731 | - | - |
| Enterprise Value (EV) 1 | 100.5 | 53.55 | 9.731 | 9.731 | 9.731 |
| P/E ratio | -8.2 x | -0.87 x | -0.31 x | -0.84 x | -0.89 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 9,878 | 35,464 | 64,191 | - | - |
| Reference price 2 | 10.17 | 1.510 | 0.1516 | 0.1516 | 0.1516 |
| Announcement Date | 7/25/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -28.99 | -31.34 | -36.04 | -41.44 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -29.2 | -32.03 | -36.21 | -40.53 |
| Net income 1 | -25.43 | -29.22 | -32.04 | -36.21 | -40.53 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.240 | -1.730 | -0.4950 | -0.1800 | -0.1700 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/25/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -7.221 | -9.82 | -6.752 | -7.427 | -8.17 | -8.987 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -8.232 | -7.221 | -7.594 | -8.293 | -8.925 |
| Net income 1 | - | -8.229 | -7.225 | -7.594 | -8.293 | -8.925 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | - | - | -0.2000 | -0.1450 | -0.1150 | -0.0600 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/14/23 | 3/15/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.59 | 0.01 | 0.73 | 2.12 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 7/25/23 | 3/15/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1516
USD
Average target price
1.5
USD
Spread / Average Target
+889.45%
EPS Revisions
- Stock Market
- Equities
- CLDI Stock
- Financials CALI BIOTPAR
